RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid

Inclusion Criteria: * 1\. Histologically or cytologically confirmed pheochromocytoma or extra-adrenal paraganglioma or carcinoid * 2\. Local, locally-advanced or metastatic disease documented as having shown progression on a scan (CT, MRI, MIBI scan) taken 2 to 12 months prior to baseline compared to a previous scan taken at any time in the past. Progression must be documented according to RECIST criteria. * 3\. Disease that is not amenable to surgery, radiation or combined modality therapy with curative intent. * 4\. Presence of at least one measurable target lesion for further evaluation according to RECIST criteria * 5\. 18 years or older * 6\. ECOG performance status 0, 1 * 7\. Previous treatment with chemotherapy, loco-regional therapy (e.g chemoembolization) are permitted providing that toxicity has resolved to ≤grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment. * 8\. Adequate organ function * 9\. A patient with the willingness to comply with the study protocol during the study period and capable of complying with it * 10\. A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages. Exclusion Criteria: * 1\. A patient with no measurable disease * 2\. Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-t…